▁clin ical ▁tri als ▁as ▁a ▁potential ▁target ed ▁treatment ▁for ▁met ast atic ▁g astr ic ▁car cin oma , ▁met ast atic ▁breast ▁cancer ▁and ▁advanced ▁he pat oc ell ular ▁car cin oma . ▁ ▁Ph ase ▁I / II ▁clin ical ▁study ▁The ▁principal ▁investig ator ▁from ▁F ud an ▁University , ▁China , ▁presented ▁results ▁of ▁Ph ase ▁I / II ▁human ▁clin ical ▁studies ▁at ▁the ▁ 2 0 0 9 ▁CS CO ▁Me eting ▁( Oct ober ▁ 1 7 , ▁ 2 0 0 9 ). ▁ ▁Can cer ▁patients ▁were ▁admin ister ed ▁varied ▁dos es ▁of ▁A pat in ib ▁daily ▁for ▁ 2 8 ▁days . ▁ ▁A pat in ib ▁was ▁well ▁toler ated ▁at ▁dos es ▁below ▁ 7 5 0   m g / day , ▁ 3 ▁of ▁ 3 ▁do se ▁limit ing ▁to xic ities ▁were ▁reported ▁at ▁ 1 0 0 0   m g / day ▁and ▁the ▁maximum ▁toler ated ▁do se ▁is ▁determined ▁to ▁be ▁ 8 5 0   m g / day . ▁ ▁The ▁investig ator ▁also ▁reported ▁of ▁ 6 5 ▁cancer ▁patients ▁treated ▁in ▁Ph ase ▁I / II , ▁ 1 . 5 4 % ▁had ▁a ▁complete ▁response , ▁ 1 2 . 3 1 % ▁had ▁a ▁partial ▁response , ▁ 6 6 . 1 5 % ▁had ▁stable ▁disease ▁and ▁ 2 0 % ▁had ▁progress ive ▁disease . ▁ ▁A ▁separate ▁published